AU2017377653B2 - Non-peptide oxytocin receptor agonists - Google Patents

Non-peptide oxytocin receptor agonists Download PDF

Info

Publication number
AU2017377653B2
AU2017377653B2 AU2017377653A AU2017377653A AU2017377653B2 AU 2017377653 B2 AU2017377653 B2 AU 2017377653B2 AU 2017377653 A AU2017377653 A AU 2017377653A AU 2017377653 A AU2017377653 A AU 2017377653A AU 2017377653 B2 AU2017377653 B2 AU 2017377653B2
Authority
AU
Australia
Prior art keywords
substituted
unsubstituted
alkyl
alkenyl
alkynyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2017377653A
Other languages
English (en)
Other versions
AU2017377653A1 (en
Inventor
Michael Bowen
William Jorgensen
Michael Kassiou
Iain McGregor
Tristan Reekie
Eryn Werry
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kinoxis Therapeutics Pty Ltd
Original Assignee
Kinoxis Therapeutics Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2016905126A external-priority patent/AU2016905126A0/en
Application filed by Kinoxis Therapeutics Pty Ltd filed Critical Kinoxis Therapeutics Pty Ltd
Publication of AU2017377653A1 publication Critical patent/AU2017377653A1/en
Assigned to Kinoxis Therapeutics Pty Ltd reassignment Kinoxis Therapeutics Pty Ltd Request for Assignment Assignors: THE UNIVERSITY OF SYDNEY
Application granted granted Critical
Publication of AU2017377653B2 publication Critical patent/AU2017377653B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyridine Compounds (AREA)
AU2017377653A 2016-12-12 2017-12-12 Non-peptide oxytocin receptor agonists Active AU2017377653B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2016905126A AU2016905126A0 (en) 2016-12-12 Non-peptide oxytocin receptor agonists
AU2016905126 2016-12-12
PCT/AU2017/051371 WO2018107216A1 (en) 2016-12-12 2017-12-12 Non-peptide oxytocin receptor agonists

Publications (2)

Publication Number Publication Date
AU2017377653A1 AU2017377653A1 (en) 2019-07-11
AU2017377653B2 true AU2017377653B2 (en) 2022-04-21

Family

ID=62557695

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2017377653A Active AU2017377653B2 (en) 2016-12-12 2017-12-12 Non-peptide oxytocin receptor agonists

Country Status (19)

Country Link
US (2) US11491165B2 (https=)
EP (2) EP4494705A3 (https=)
JP (3) JP7089649B2 (https=)
KR (1) KR102561721B1 (https=)
CN (1) CN110248944A (https=)
AU (1) AU2017377653B2 (https=)
BR (1) BR112019012049A2 (https=)
CA (1) CA3046809A1 (https=)
DK (1) DK3551631T3 (https=)
ES (1) ES3001195T3 (https=)
FI (1) FI3551631T3 (https=)
HU (1) HUE070078T2 (https=)
IL (1) IL267276B2 (https=)
MX (1) MX2019006942A (https=)
PL (1) PL3551631T3 (https=)
PT (1) PT3551631T (https=)
RU (1) RU2019120162A (https=)
SI (1) SI3551631T1 (https=)
WO (1) WO2018107216A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220079953A1 (en) * 2018-11-23 2022-03-17 The University Of Sydney Methods for management of weight
KR20220063198A (ko) * 2019-09-06 2022-05-17 키녹시스 테라퓨틱스 피티와이 리미티드 아편유사제 금단의 치료
JP2022548581A (ja) 2019-09-13 2022-11-21 オリゲニス ゲーエムベーハー 例えば自己免疫疾患の処置のための、ＬＲＲＫ２、ＮＵＡＫ１および／またはＴＹＫ２キナーゼモジュレータとしての１，４－ジヒドロベンゾ［ｄ］ピラゾロ［３，４－ｆ］［１，３］ジアゼピン誘導体および関連する化合物
JP2023552485A (ja) * 2020-12-14 2023-12-15 キノシス・セラピューティクス・ピーティーワイ・リミテッド オキシトシン受容体モジュレーター
AU2022240104A1 (en) * 2021-03-18 2023-10-05 Kinoxis Therapeutics Pty Ltd Methods of treatment

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003000692A2 (en) * 2001-06-25 2003-01-03 Ferring Bv Oxytocin agonists
WO2005023812A2 (en) * 2003-09-05 2005-03-17 Ferring B.V. Piperazines as oxytocin agonists
WO2006021213A2 (en) * 2004-08-24 2006-03-02 Ferring B.V. Vasopressin v1a antagonists
WO2010097576A1 (en) * 2009-02-27 2010-09-02 Vantia Limited 1, 4-disubstituted piperidines as vasopressin receptor via antagonists

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3770762A (en) * 1972-08-29 1973-11-06 Parke Davis & Co Diazepine compounds and methods for their production
AR002459A1 (es) 1995-01-17 1998-03-25 American Cyanamid Co Antagonistas de vasopresina de benzacepina triciclicos, una composicion farmaceutica que los contiene, un metodo para tratar enfermedades y unprocedimiento para su preparacion.
US5536718A (en) * 1995-01-17 1996-07-16 American Cyanamid Company Tricyclic benzazepine vasopressin antagonists
GB0120051D0 (en) * 2001-08-16 2001-10-10 Ferring Bv Oxytocin agonists
EP1449844A1 (en) * 2003-02-14 2004-08-25 Ferring B.V. benzamide derivatives as oxytocin agonists and vasopressin antagonists
US7342112B2 (en) * 2003-07-01 2008-03-11 Ppg Industries Ohio, Inc. Photochromic compounds
KR100858262B1 (ko) * 2004-10-13 2008-09-11 에프. 호프만-라 로슈 아게 Ｃｄｋ2 및 혈관신생에 대한 저해제로서 유용하고, 유방암,대장암, 폐암 및 전립선암의 치료용으로 유용한이중치환된 피라졸로벤조디아제핀
CN101203516A (zh) * 2005-04-05 2008-06-18 法马科皮亚公司 用于免疫抑制的嘌呤及咪唑并吡啶衍生物
AU2006306547A1 (en) 2005-10-24 2007-05-03 Wyeth Tricyclic compounds useful as oxytocin receptor agonists
WO2008103382A1 (en) * 2007-02-20 2008-08-28 Sergey Kozmin Method for assembling high-purity chemical libraries, compounds suppressing acetyl coenzyme a carboxylase activities discovered by same
US10508108B2 (en) * 2014-12-05 2019-12-17 Merck Sharp & Dohme Corp. Tricyclic compounds as inhibitors of mutant IDH enzymes
PL3328864T3 (pl) * 2015-07-06 2023-02-27 Kinoxis Therapeutics Pty Ltd Związki i kompozycje terapeutyczne do leczenia zaburzeń społecznych i zaburzeń związanych z używaniem substancji psychoaktywnych

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003000692A2 (en) * 2001-06-25 2003-01-03 Ferring Bv Oxytocin agonists
WO2005023812A2 (en) * 2003-09-05 2005-03-17 Ferring B.V. Piperazines as oxytocin agonists
WO2006021213A2 (en) * 2004-08-24 2006-03-02 Ferring B.V. Vasopressin v1a antagonists
WO2010097576A1 (en) * 2009-02-27 2010-09-02 Vantia Limited 1, 4-disubstituted piperidines as vasopressin receptor via antagonists

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Frantz, M.-C. et al.; "Subtlety of the Structure-Affinity and Structure-Efficacy Relationships around a Nonpeptide Oxytocin Receptor Agonist"; J. Med. Chem., 53, 1546-1562 (2010). DOI: 10.1021/jm901084f. *
Jorgensen, W.T. et al.; "Flexible analogues of WAY-267,464: Synthesis and pharmacology at the human oxytocin and vasopressin 1a receptors"; Eur. J. Med. Chem., 108, 730-740 (2016). DOI: 10.1016/j.ejmech.2015.11.050. *
Karpenko, I.A. et al.; "Selective Nonpeptidic Fluorescent Ligands for Oxytocin Receptor: Design, Synthesis, and Application to Time-Resolved FRET Binding Assay"; J. Med. Chem., 58, 2547-2552 (2015). DOI: 10.1021/jm501395b. *

Also Published As

Publication number Publication date
CN110248944A (zh) 2019-09-17
KR102561721B1 (ko) 2023-07-28
US20200000823A1 (en) 2020-01-02
IL267276B1 (en) 2024-05-01
BR112019012049A2 (pt) 2019-11-12
EP3551631A1 (en) 2019-10-16
JP2024107136A (ja) 2024-08-08
EP3551631A4 (en) 2020-07-15
JP2022097655A (ja) 2022-06-30
RU2019120162A (ru) 2021-01-12
ES3001195T3 (es) 2025-03-04
PL3551631T3 (pl) 2025-03-24
HUE070078T2 (hu) 2025-05-28
IL267276B2 (en) 2024-09-01
DK3551631T3 (en) 2025-02-17
US20230330103A1 (en) 2023-10-19
CA3046809A1 (en) 2018-06-21
MX2019006942A (es) 2019-10-21
EP3551631B1 (en) 2024-11-13
FI3551631T3 (fi) 2025-01-16
EP4494705A3 (en) 2025-04-02
EP3551631B9 (en) 2025-02-26
JP2020500924A (ja) 2020-01-16
US11491165B2 (en) 2022-11-08
RU2019120162A3 (https=) 2021-01-28
WO2018107216A1 (en) 2018-06-21
IL267276A (en) 2019-08-29
PT3551631T (pt) 2024-12-10
SI3551631T1 (sl) 2025-03-31
AU2017377653A1 (en) 2019-07-11
KR20190091534A (ko) 2019-08-06
EP4494705A2 (en) 2025-01-22
JP7089649B2 (ja) 2022-06-23
NZ754890A (en) 2025-03-28

Similar Documents

Publication Publication Date Title
AU2017377653B2 (en) Non-peptide oxytocin receptor agonists
ES2676826T3 (es) Compuestos basados en imidazo[1,2-b]piridazina, composiciones que los comprenden y usos de los mismos
ES2901471T3 (es) Agonistas del receptor 2 de formilpéptido y del receptor 1 de formilpéptido de piperidinona
CN105358532B (zh) 杂环化合物和它们的使用方法
BR112015010072B1 (pt) Compostos, processo para a preparação dos referidos compostos, medicamento comprendendo os mesmos e seu uso relacionado
AU2006322060A1 (en) Lactam compounds and methods of using the same
CA3105681A1 (en) Pyridazinone derivative
JP2018076297A (ja) 複素環式化合物およびその使用方法
TW200524878A (en) Gabanergic modulators
JP2025091422A (ja) 置換ピリジニル化合物およびその使用
AU2019247842B2 (en) Opioid receptor modulators and products and methods related thereto
KR102804113B1 (ko) 알킬 다이하이드로퀴놀린 설폰아마이드 화합물
EP3145933B1 (en) Nampt inhibitors and methods
CA3100954A1 (en) Cyanotriazole compounds and uses thereof
JP2002544258A (ja) イオンチャネル調節剤
CN111148734B (zh) 吡咯-2-甲酰胺类化合物及其制备方法和用途
US20240327376A1 (en) Picolinamide compounds as selective phd1 inhibitors, compositions, and methods of use
HK40014275A (en) Non-peptide oxytocin receptor agonists
WO2025119380A1 (zh) 雌激素受体调节剂及其用途
CN118414330A (zh) 作为rxfp1激动剂的萘和喹啉类似物
BR122024019626A2 (pt) Composto agonista receptor 5-ht1f, composição farmacêutica, e usos

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: KINOXIS THERAPEUTICS PTY LTD

Free format text: FORMER APPLICANT(S): THE UNIVERSITY OF SYDNEY

FGA Letters patent sealed or granted (standard patent)